BioXcel Therapeutics, Inc. (BTAI) — Financial statements
Income statement, balance sheet, and cash flow for BioXcel Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.64↓71.7% | 2↑64.2% | 1↑268.0% | 0.38 | 0.00 | |
| Cost of Revenue | 0.46↓78.3% | 2↑70.1% | 1↑6200.0% | 0.02↓93.3% | 0.30 | |
| Gross Profit | 0.18↑44.7% | 0.12↑2.5% | 0.12↓66.2% | 0.36↑219.5% | -0.30 | |
| Operating Expenses | ||||||
| R&D Expenses | 30↓0.6% | 30↓63.9% | 84↓7.6% | 91↑76.9% | 52 | |
| General & Administrative Expenses | 0.00↓100.0% | 33↓47.9% | 64↑13.9% | 56 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 1↓93.0% | 20↑53.0% | 13 | 0.00 | |
| SG&A Expenses | 20↓40.6% | 34↓58.6% | 83↑21.3% | 69↑27.3% | 54 | |
| Other Expenses | -0.86↓135.3% | 2↓41.4% | 4 | 0.00 | 0.00 | |
| Operating Expenses | 50↓26.0% | 67↓60.8% | 172↑7.4% | 160↑51.5% | 106 | |
| Total Costs & Expenses | 50↓27.6% | 70↓59.9% | 173↑8.2% | 160↑51.1% | 106 | |
| Operating Results | ||||||
| Operating Income | -50↑26.1% | -67↑60.9% | -172↓7.6% | -160↓50.8% | -106 | |
| Depreciation & Amortization | 0.30↓2.9% | 0.31↓2.8% | 0.32↓2.8% | 0.33↑10.1% | 0.30 | |
| EBITDA | -49↓11.9% | -44↑73.3% | -165↓5.2% | -157↓46.9% | -107 | |
| EBIT | -50↓11.8% | -44↑73.2% | -166↓5.2% | -158↓46.8% | -107 | |
| Interest & Other Income | ||||||
| Net Interest Income | -16↓27.1% | -13↓63.4% | -8↓34.8% | -6↓15691.7% | -0.04 | |
| Interest Income | 1↓59.0% | 3↓53.9% | 6↑123.5% | 3↑63100.0% | 0.00 | |
| Interest Expense | 17↑12.3% | 15↑13.6% | 13↑62.1% | 8↑20432.5% | 0.04 | |
| Non-Operating Income | 0.00↑100.0% | -23↓276.9% | -6↓187.6% | -2↓250.3% | 1 | |
| Other Income / Expenses | -20↓364.1% | 8↑205.2% | -7↓19.0% | -6↓337.2% | -1 | |
| Income Before Tax | -70↓17.3% | -60↑66.7% | -179↓8.0% | -166↓54.5% | -107 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.36 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -70↓17.3% | -60↑66.7% | -179↓8.0% | -166↓55.0% | -107 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -70↓17.3% | -60↑66.7% | -179↓8.0% | -166↓55.0% | -107 | |
| Bottom-Line Net Income | -70↓17.3% | -60↑66.7% | -179↓8.0% | -166↓55.0% | -107 | |
| EPS (Basic) | -5.73↑75.6% | -23.51↑76.1% | -98.35↓3.9% | -94.67↓45.9% | -64.87 | |
| EPS (Diluted) | -5.73↑75.6% | -23.51↑76.1% | -98.35↓3.9% | -94.67↓45.9% | -64.87 | |
| Weighted Average Shares | 12↑381.6% | 3↑39.2% | 2↑4.0% | 2↑6.2% | 2 | |
| Weighted Average Diluted Shares | 12↑381.6% | 3↑39.2% | 2↑4.0% | 2↑6.2% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.